Login to Your Account



BioInvent Stock Surges With $190M Genentech Antibody Deal

By Cormac Sheridan


Tuesday, January 16, 2007
BioInvent International AB added $15 million to its coffers and could earn up to $175 million more in milestones from an agreement with Genentech Inc. to co-develop its preclinical monoclonal antibody BI-204, which is in development for prevention of acute coronary syndrome. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription